TCTR20210520004已完成不适用
Safety and immunogenicity of inactivated COVID-19 vaccine and virus vector vaccine in Thai adults with previous infection: Clinical trial
The National Research Council of Thailand0 个研究点目标入组 120 人开始时间: 2021年5月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
The anti-RBD IgG titer after vaccination in previously infected participants was significantly boosted. At 28 days after a single dose vaccination, the short and long interval group possessed anti-RBD IgG with 12.87 fold (1549 BAU/mL) and 73.79 fold (2258 BAU/mL) compared to baseline following AZD1222 vaccination. In comparison, the increase of anti-RBD IgG with 3.12 fold (235 BAU/mL) and 7.79 fold (257 BAU/mL) were observed in short and long interval groups after a single dose of CoronaVac vaccine.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Healthy individuals above 18 years of age
- •2. History of COVID-19 infection confirmed by RT-PCR, with no symptoms for at least 28 days
- •3. Not in immunosuppresive conditions
排除标准
- •1. Having received any COVID-19 vaccinations
- •2. Are being treated, hospitalized or have symptoms of COVID-19
研究者
相似试验
Unknown
4 期
Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis PopulationHemolysisCOVID-19NCT05480436China National Biotec Group Company Limited1,200
Unknown
4 期
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies VaccineCOVID-19RabiesNCT05453487China National Biotec Group Company Limited360
已完成
4 期
Safety and Immunogenicity of inactivated COVID-19 vaccine in Thai adultsSafety and Immunogenicity of inactivated COVID-19 vaccine in Thai adultsCOVID-19, Vaccine, inactivated, adultsTCTR20210308003ational Reseach Council, Thailand182
已完成
不适用
Immunogenicity Induced by COVID-19 Vaccines in Mexican PopulationCOVID-19 VaccineNCT06597370National Polytechnic Institute, Mexico80
已完成
2 期
BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive VolunteersHealthyInfection ImmunizationNCT04824638ANRS, Emerging Infectious Diseases267